Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성종미 | - |
dc.date.accessioned | 2020-05-04T16:30:09Z | - |
dc.date.available | 2020-05-04T16:30:09Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1837-9664 | - |
dc.identifier.other | OAK-26858 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/253882 | - |
dc.description.abstract | Purpose: To conduct a population-based study to determine whether the use of GnRH agonist and antiandrogens are associated with an increased risk of cardio-cerebrovascular disease (CCVD) in Asian patients with prostate cancer using the National Health Insurance Service-Elderly Cohort Database (NHIS-ECD). Materials and Methods: We included a total of 2,413 men aged 60 years or older with prostate cancer between January 2003 and December 2008. Outcomes of interest included the first occurrence of cardiovascular events [acute myocardial infarction (AMI), ischemic heart disease (IHD)] and cerebrovascular events [ischemic stroke (IS), and cerebrovascular disease (CVD)]. Results: The 5-year AMI-free rates of patients diagnosed with prostate cancer and treated with GnRH agonists, antiandrogens alone, or androgen deprivation therapy (ADT)-naive interventions were 97.0%, 96.5%, and 98.3%, respectively, while the 5-year IHD-free rates were 93.2%, 92.3%, and 94.5%, respectively. Exposure to GnRH agonists or antiandrogen regimens did not significantly increase the risk of AMI or IHD compared to ADT-naive treatment in multivariate Cox proportional-hazards models after adjusting for other covariates. Five-year IS-free rates of patients exposed to GnRH agonists, antiandrogens alone, and those with ADT-naive prostate cancer were 94.8%, 94.7%, and 95.5%, respectively, while the five-year CVD-free rates were 92.9%, 93.3%, and 94.6%, respectively. Cox proportional-hazards models also failed to show that men who received GnRH agonist or antiandrogen treatment alone carried a significantly increased risk for IS or CVD compared to ADT-naive patients. Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naive prostate cancer. | - |
dc.language | English | - |
dc.publisher | IVYSPRING INT PUBL | - |
dc.subject | Prostatic Neoplasms | - |
dc.subject | Gonadotropirt-Releasing Hormone | - |
dc.subject | Antiandrogens | - |
dc.subject | Cerebrovascular Disease | - |
dc.subject | Cardiovascular Diseases | - |
dc.title | Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study | - |
dc.type | Article | - |
dc.relation.issue | 14 | - |
dc.relation.volume | 11 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 4015 | - |
dc.relation.lastpage | 4022 | - |
dc.relation.journaltitle | JOURNAL OF CANCER | - |
dc.identifier.doi | 10.7150/jca.38237 | - |
dc.identifier.wosid | WOS:000526085700002 | - |
dc.author.google | Seong, Jong-Mi | - |
dc.author.google | Shin, Dongho | - |
dc.author.google | Sung, Jae Woo | - |
dc.author.google | Cho, Shinjay | - |
dc.author.google | Yang, Jonghyup | - |
dc.author.google | Kang, Sungmin | - |
dc.author.google | Moon, Hyong Woo | - |
dc.author.google | Lee, Kyu Won | - |
dc.author.google | Ha, U-Syn | - |
dc.contributor.scopusid | 성종미(36712609800) | - |
dc.date.modifydate | 20230208115751 | - |